Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$110.35 +0.2%	$106.39	$72.21 ▼ $139.13	$5.42B	0.46	666,403 shs	227,454 shs
CRSP CRISPR Therapeutics	$54.52 +3.4%	$43.29	$30.04 ▼ $63.68	$4.71B	1.82	1.96 million shs	2.41 million shs
MESO Mesoblast	$11.19 +2.1%	$11.20	$5.78 ▼ $22.00	$1.43B	2.39	276,569 shs	44,396 shs
TLX Telix Pharmaceuticals	$15.65 +0.7%	$16.56	$13.61 ▼ $30.36	$5.29B	N/A	29,003 shs	4,829 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-1.97%	+1.58%	+5.78%	+5.41%	+33.00%
CRSP CRISPR Therapeutics	-6.54%	-3.81%	+27.49%	+39.57%	-8.23%
MESO Mesoblast	-1.88%	+4.88%	-6.96%	+6.30%	+43.27%
TLX Telix Pharmaceuticals	-0.26%	-1.02%	-3.48%	-6.11%	+1,552,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6947 of 5 stars	4.5	1.0	0.0	4.5	2.2	4.2	0.6
CRSP CRISPR Therapeutics	3.2465 of 5 stars	4.3	1.0	0.0	0.0	3.2	2.5	0.6
MESO Mesoblast	2.3311 of 5 stars	3.5	3.0	0.0	0.0	2.0	0.8	0.6
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	56.17% Upside
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	31.60% Upside
MESO Mesoblast	3.00	Buy	$18.00	60.93% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.33	42.75% Upside

Current Analyst Ratings Breakdown

Latest MESO, AXSM, TLX, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	TLX Telix Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
7/3/2025	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/12/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$432.16M	12.57	N/A	N/A	$1.18 per share	93.52
CRSP CRISPR Therapeutics	$35M	134.53	N/A	N/A	$22.64 per share	2.41
MESO Mesoblast	$5.67M	252.06	N/A	N/A	$4.21 per share	2.66
TLX Telix Pharmaceuticals	$516.72M	10.25	$0.11 per share	136.35	$1.12 per share	13.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	39.13	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	32.59	N/A	N/A	N/A	N/A	N/A

Latest MESO, AXSM, TLX, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.54	N/A	N/A	N/A	$6.44 million	N/A
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
CRSP CRISPR Therapeutics	N/A	15.64	15.64
MESO Mesoblast	0.22	0.96	0.63
TLX Telix Pharmaceuticals	0.99	2.78	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CRSP CRISPR Therapeutics	69.20%
MESO Mesoblast	1.43%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.40%
CRSP CRISPR Therapeutics	4.10%
MESO Mesoblast	18.80%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.21 million	Optionable
CRSP CRISPR Therapeutics	460	86.36 million	82.82 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.38 million	N/A	N/A

MESO, AXSM, TLX, and CRSP Headlines

Recent News About These Companies

William Blair Has Negative Outlook of TLX FY2025 Earnings

July 16 at 6:46 AM | marketbeat.com

Missing the first double on this biotech star

July 15 at 9:15 PM | msn.com

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

July 15 at 11:31 AM | msn.com

William Blair Reiterates Outperform Rating for Telix Pharmaceuticals (NASDAQ:TLX)

July 12, 2025 | americanbankingnews.com

Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially ...

July 11, 2025 | insidermonkey.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Should You Sell?

July 10, 2025 | marketbeat.com

Gozellix Receives Permanent HCPCS Code

July 9, 2025 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - What's Next?

July 9, 2025 | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from William Blair

July 9, 2025 | marketbeat.com

Telix shares jump 7% on big US news

July 8, 2025 | msn.com

Telix Pharmaceuticals Stock Short Interest Report | NASDAQ:TLX - Benzinga

July 3, 2025 | benzinga.com

HC Wainwright & Co. Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Buy Recommendation

July 3, 2025 | msn.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What Happened

July 3, 2025 | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Coverage Initiated at HC Wainwright

July 3, 2025 | marketbeat.com

Up 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'

June 30, 2025 | msn.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - Here's What Happened

June 27, 2025 | marketbeat.com

Telix Pharmaceuticals Limited: Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses

June 25, 2025 | finanznachrichten.de

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?

June 23, 2025 | marketbeat.com

Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT

June 23, 2025 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?

June 20, 2025 | marketbeat.com

Telix Precision Medicine Announces AlFluor Radiochemistry Platform

June 20, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, AXSM, TLX, and CRSP Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$110.35 +0.23 (+0.21%)

As of 01:58 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

CRISPR Therapeutics NASDAQ:CRSP

$54.52 +1.79 (+3.39%)

As of 01:58 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Mesoblast NASDAQ:MESO

$11.18 +0.23 (+2.05%)

As of 01:52 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Telix Pharmaceuticals NASDAQ:TLX

$15.64 +0.12 (+0.74%)

As of 01:54 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time